A new publication involving desmopressin was announced on September 16, 2026. The study, titled "DDAVP Challenges in 170 Children With von Willebrand Disease: Response Classification Varies According to Criteria Used," appears in Haemophilia, the official journal of the World Federation of Hemophilia. Desmopressin, also known as DDAVP, remains an approved compound. The publication is listed under PubMed ID 42750215. This brief reports only that the publication exists and identifies its title, journal, and date, as provided in the source record. No study findings, outcomes, or response data are included here, since none were specified in the available event information. Readers interested in the details of this research should consult the full text through the original journal listing. For general background on desmopressin, including its approved uses and regulatory status, readers can refer to the compound overview for further context.
New Publication on DDAVP Challenges in Children With von Willebrand Disease
See the full desmopressin overview
Source: https://pubmed.ncbi.nlm.nih.gov/42750215/